Nozinan (Levomepromazine Hydrochloride)

Levomepromazine Hydrochloride, the active ingredient in Nozinan, is a phenothiazine antipsychotic presented as a tablet for oral use. It is employed in the management of severe agitation, psychotic disorders, and nausea in palliative care settings. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a broad‑spectrum phenothiazine that acts on multiple neurotransmitter pathways, particularly dopamine and serotonin receptors.

- Severe agitation in terminal illness: helps control distress and restlessness. - Psychotic disorders (schizophrenia, acute psychosis): reduces hallucinations and delusions. - Nausea and vomiting in palliative care: provides anti‑emetic relief when other agents are insufficient.

Levomepromazine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Orthostatic hypotension - Blurred vision - Weight gain

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Neuroleptic malignant syndrome - Torsades de pointes or other serious cardiac arrhythmias - Severe hypotension - Agranulocytosis - Hepatotoxicity

When prescribing Levov…

- Monitor: Regular cardiovascular monitoring to ensure stable blood pressure and heart rate during initiation and dose adjustments. - Assess : Baseline electro‑  When taking Nozinan (levomepromazine), it is critical to observe several key safety precautions to minimize the risk of serious adverse effects. This potent antipsychotic and sedative affects multiple systems in the body, requiring careful tracking and behavioral adjustments